This is the "Home" page of the "Grand Rounds 01/18/17 @ BID-Needham: Dr. Richard S. Beaser" guide.
Alternate Page for Screenreader Users
Skip to Page Navigation
Skip to Page Content

Grand Rounds 01/18/17 @ BID-Needham: Dr. Richard S. Beaser  

Advancing to Insulin Replacement Therapy: When, Why and How?
Last Updated: Jan 19, 2017 URL: http://bidmc.libguides.com/Beaser/2017/Jan Print Guide RSS Updates

Home Print Page
  Search: 
 

Speaker: Date: Topic

Richard S. Beaser, MD

Jan. 18, 2017

Advancing to Insulin Replacement Therapy: When, Why, and How?

      

    Disclosures

    Director of Medical Education and Committee Members have indicated they have no relevant financial interests or relationships to disclose. Faculty has indicated no relevant financial interests or relationships to disclose.

        

      Responsibility for Content

      The PowerPoint presentation, Take-Away points, Objectives,  Link, and Abstract links were sent by Medical Library Services and the CME Committee.

      Diane E. Young, Information Specialist

      dyoung3@bidmc.harvard.edu

       

          

        Take-Away Points of the Presentation

        1. When treating Type 2 diabetes with insulin, treatment goals, selection from various program design options, and monitoring recommendations must be individualized for patient physiologic needs, self-care abilities, and safety.

        2. Sequential advancement of insulin treatment designs is an important part of that individualized approach to therapy.

        3. Basal-bolus regimens require more injections but provide better insulin coverage and glycemic control.

        4. Don't delay initiation of insulin: Self-assess office capabilities in the context of insulin treatment support.

            

          Objectives of the Presentation

          Participants should be able to:

          • Identify clinical indications for initiation of basal insulin for type 2 diabetes based on the natural history of type 2 diabetes.
          • Describe options for advancing insulin therapy for type 2 diabetes beyond basal-only, and the rationale for use of each.
          • Discuss indications for use of a physiologic insulin program using the "basal/bolus" construct, various means to design such a program, and how such a program might be implemented in a clinical practice setting.
              

            Links to Abstracts of Articles Cited (contact Diane Young for full-text articles at dyoung3@bidmc.harvard.edu)

             

            Feedback Welcome

            Was this information helpful?

            How useful is this page?
            (1 = Not Useful, 5 = Very Useful!)

            Additional comments:


            Your Email:


            THIS SITE IS MAINTAINED BY KNOWLEDGE SERVICES AT THE BETH ISRAEL DEACONESS MEDICAL CENTER.
            CLICK HERE TO ASK A QUESTION OR REPORT A PROBLEM.

            Description

            Loading  Loading...

            Tip